Novavax, Inc. is revising full year 2022 total revenue guidance to $2 billion to $2.3 billion. Total revenue reflects all sources, including product sales of Nuvaxovid by Novavax, grants revenue, royalties and other revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.95 USD | -4.82% | +1.54% | -17.71% |
Apr. 15 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.71% | 581M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax, Inc. Is Revises Revenue Guidance for Full Year 2022